Evidence question

PubMed sourcedAbstract-based analysisUpdated Sep 2026Human reviewedUpdated Aug 2026

Evidence / Menopause & Women's Health

CoverageMenopause & Women's Health

Is fezolinetant effective for menopausal hot flashes?

Reviewed by Neal Rouzier, MD, Preventive Medicine · Aug 2026

Updated Aug 2026·10 studies analyzed·2 core studies·Applies to: perimenopausal and early postmenopausal women

Bottom line

Fezolinetant, a neurokinin-3 receptor antagonist, reduced moderate-to-severe vasomotor symptoms in randomized trials of postmenopausal women. It offers a non-hormonal option when estrogen is contraindicated or declined.[1–6]

Evidence confidence

Evidence Confidence

High
LimitedModerateHigh

Multiple high-quality studies directly address this question, with generally consistent findings.

Key uncertainty. Long-term safety beyond trial follow-up is still accumulating.

Ask RAGMD

Get the live evidence synthesis

10 complimentary queries. Full clinical intelligence — PubMed citations, conflict analysis, Evidence Confidence — with 7-day free trial.

Ask this questionStart free trialWhy physicians use RAGMD

Also asked

Fezolinetant vasomotor symptoms▼

Fezolinetant, a neurokinin-3 receptor antagonist, reduced moderate-to-severe vasomotor symptoms in randomized trials of postmenopausal women. It offers a non-hormonal option when estrogen is contraindicated or declined.

NK3 antagonist hot flashes▼

Fezolinetant, a neurokinin-3 receptor antagonist, reduced moderate-to-severe vasomotor symptoms in randomized trials of postmenopausal women. It offers a non-hormonal option when estrogen is contraindicated or declined.

Body of evidence

Clinical Evidence Brief

RAGMD analyzed 10 relevant studies.

Overall finding

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. 2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. 2 studies address venous thromboembolism, with weighted findings showing a positive association. 2 studies address breast cancer, with weighted findings showing a positive association. 4 randomized or systematic-review reports and 5 observational studies address treatment. Offer fezolinetant when vasomotor symptoms require treatment and systemic estrogen is contraindicated or unwanted.

Evidence by outcome

Direction: ↑ Favors treatment / reassuring · ↓ Harm signal · ↔ No clear effect · ± Mixed · ↗ Observational link · ? Unclear

Mixed

Vasomotor symptom associations

moderate · 8 studies

8 studies address vasomotor symptom associations, with weighted findings showing mixed findings. This is a patient-reported / subjective outcome.

Patient-reported

Studies

PMID 40253593PMID 38016166PMID 41307293PMID 29322164PMID 26838086PMID 36749328PMID 42606770PMID 34513605
Negative link

Long-term cognitive decline / dementia

moderate · 2 studies

2 studies address long-term cognitive decline / dementia, with weighted findings showing a negative association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 34513605
Positive link

Venous thromboembolism

moderate · 2 studies

2 studies address venous thromboembolism, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Positive link

Breast cancer

moderate · 2 studies

2 studies address breast cancer, with weighted findings showing a positive association. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293PMID 36749328
Unclear

Mortality

moderate · 1 study

1 study addresses mortality, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293
Unclear

Fertility / spermatogenesis

moderate · 1 study

1 study addresses fertility / spermatogenesis, with weighted findings showing unclear findings. This is an objectively measured outcome. This is a hard clinical endpoint.

Objectively measured · Hard clinical endpoint

Studies

PMID 41307293

Magnitude / clinical importance

Validated effect estimates in the analyzed set include or 4; RR 1.17. Statistical significance is not the same as clinical importance.

Where quantified, effects were often statistically detectable but small in absolute terms.

Agreement across studies

Most studies agree on vasomotor symptom associations (mixed findings), while long-term cognitive decline / dementia findings are a negative association and more consistent across domains.

Supports main conclusion: 5 · Neutral / mixed: 5 · Credible conflicting: 0

Study counts describe the landscape; RAGMD weights studies according to design, quality, and directness.

Conflicting findings

  • INTRODUCTION: Fezolinetant is a first-in-class non-hormonal pharmacological treatment recently approved for moderate-to-severe vasomotor symptoms (VMS) associated with menopause.
  • The only HT regimens that showed significantly greater efficacy than fezolinetant 45 mg on any of the outcomes analyzed are not available in the United States.
  • Long-term follow-up of women using hormone therapy suggests that the risk profiles vary between combined hormone therapy and oestrogen-only therapy.
  • Brain fog, referring to menopause-related subjective cognitive difficulties, is common in midlife women.

Risks & harms

1 study reports safety-relevant findings. Design mix: Narrative review. Rare-event inference should not rest on underpowered trials alone.

Who this applies to

Most studies included perimenopausal and early postmenopausal women.

What remains uncertain

  • Long-term safety beyond trial follow-up is still accumulating.
  • Long-term safety beyond trial follow-up is still accumulating.
  • Typical subjective cognitive complaints are not established as equivalent to dementia.

Clinical takeaway

Offer fezolinetant when vasomotor symptoms require treatment and systemic estrogen is contraindicated or unwanted. Monitor liver enzymes per labeling and counsel that long-term safety data are still accumulating beyond trial follow-up.

Mixed

Vasomotor symptom associations?

Mixed findings

moderate[40253593 · 38016166 · 41307293 · 29322164 · 26838086 · 36749328 · 42606770 · 34513605]

Negative link

Long-term cognitive decline / dementia?

A negative association

moderate[41307293 · 34513605]

Positive link

Venous thromboembolism?

A positive association

moderate[41307293 · 36749328]

Positive link

Breast cancer?

A positive association

moderate[41307293 · 36749328]

Unclear

Mortality?

Unclear findings

moderate[41307293]

Unclear

Fertility / spermatogenesis?

Unclear findings

moderate[41307293]

Unclear

Fractures?

Unclear findings

moderate[41307293]

Mixed

Mood-related cognitive symptoms?

Mixed findings

moderate[29322164]

4 randomized or systematic-review reports and 5 observational studies address treatment. Weighted treatment findings show mixed findings.

4 RCT / systematic review · 5 observational

Large randomized trials strongly influence the conclusion

2 landmark studies with randomized or systematic-review designs strongly inform this conclusion.

Supporting studies provide additional context

8 supporting studies add context beyond the core evidence base.

Regimen & duration

Differences in hormone type, dose, duration, and patient population affect how results should be interpreted.

Long-term uncertainty

Evidence beyond long follow-up windows and in certain subgroups remains less complete.

10 analyzed studies

Strongest evidence

Expert review of clinical pharmacology2025

Landmark studyPMID 40253593

A profile of safety and efficacy of fezolinetant for the treatment of menopausal vasomotor symptoms.

INTRODUCTION: Fezolinetant is a first-in-class non-hormonal pharmacological treatment recently approved for moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Its mechanism of action selectively targets the pathophysiology of VMS at hypothalamic level, antagonizing binding of neurokinin B, overexpressed in estrogen deprived menopausal women, to the neurokinin 3 receptor (NK3R) in the thermoregulatory center.

Review
Evidence
Relevance
Menopause (New York, N.Y.)2024

Landmark studyPMID 38016166

Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.

The only HT regimens that showed significantly greater efficacy than fezolinetant 45 mg on any of the outcomes analyzed are not available in the United States. Fezolinetant 45 mg once daily was statistically significantly more effective than other non-HTs in reducing the frequency of moderate to severe VMS.

Systematic review
Evidence
Relevance

Supporting literature

Long-term hormone therapy for perimenopausal and postmenopausal women.

Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial.

Hormone Therapy for Relieving Postmenopausal Vasomotor Symptoms: A Systematic Review.

+5 more

More in this focus area

Related evidence analyses

Other structured clinical questions in Menopause & Women's Health.

Does hormone replacement therapy increase breast cancer risk?

Combined estrogen-progestin therapy is associated with a small increased breast cancer risk in WHI and observational data. Estrogen-alone in hysterectomized women showed lower risk in WHI, but interpretation depends on regimen, duration, and individual risk factors.

10 linked studies

Does hormone replacement therapy reduce cardiovascular risk in early menopause?

The timing hypothesis suggests earlier initiation may differ from late initiation, where WHI showed harm for combined therapy. Current guidelines emphasize individualized risk assessment rather than routine cardioprotection.

14 linked studies

Does hormone replacement therapy increase venous thromboembolism risk?

Oral estrogen increases venous thromboembolism risk compared with no therapy. Transdermal estrogen appears to carry lower thrombotic risk in observational studies and is often preferred in women at elevated VTE risk.

14 linked studies

Is there a critical timing window for cardiovascular benefit from HRT?

The critical-window concept proposes that starting HRT closer to menopause may yield different cardiovascular effects than starting later. WHI subgroup analyses inform but do not prove this hypothesis for routine practice.

14 linked studies

Go deeper on Menopause & Women's Health

Full evidence synthesis, study comparisons, conflicting evidence, and expert commentary are available with RAGMD. Ask follow-up questions, explore related topics, and see how the evidence has evolved.

Ask RAGMDExplore Menopause & Women's HealthView pricing